Home/Pipeline/Stoboclo®/Osenvelt®

Stoboclo®/Osenvelt®

Osteoporosis

MarketedApproved

Key Facts

Indication

Osteoporosis

Phase

Marketed

Status

Approved

Company

Celltrion

About Celltrion

Celltrion's mission is to promote patient health by making advanced biologics affordable and accessible globally. It has achieved this by evolving from a contract manufacturer into a vertically integrated powerhouse, becoming the world's leading biosimilar producer with a robust pipeline. Its core strategy leverages massive, FDA/EMA-certified manufacturing capacity, a direct global sales network, and a deep R&D pipeline spanning biosimilars and novel biologics to drive growth and secure long-term market leadership.

View full company profile

Therapeutic Areas

Immunology Oncology Autoimmune Diseases Ophthalmology Respiratory

Other Osteoporosis Drugs

Drug	Company	Phase	Status
Teriparatide	Epygen Biotech	Not Disclosed	Active
AGA2118	Angitia Biopharmaceuticals	Phase 2	Active
Teriparatide (PTH 1-34) Process	Numaferm	Commercial	Active
Recombinant Teriparatide	Paras Biopharmaceuticals Finland	Pre-clinical	Active
SHR-1222	Jiangsu Hengrui Medicine	Phase III	Active
Biosimilar Denosumab	Richter Gedeon	Phase III	Active
Teriparatide Injection	Amphastar Pharmaceuticals	Marketed	Generic (Launched)